Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD

Transplant Immunology

Volumn 17, Issue 3, 2007, Pages 203-210

  Sebelin Wulf, Kathrin ^a   Nguyen, Tuan D ^b   Oertel, Stephan ^a   Papp Vary, Matthias ^a   Trappe, Ralf Ulrich ^a   Schulzki, Antje ^a   Pezzutto, Antonio ^a   Riess, Hanno ^a   Subklewe, Marion ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

CD4 T cells; CD8 T cells; EBV; PTLD

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1;

ADULT; AGED; ARTICLE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNE DEFICIENCY; LYMPHOPROLIFERATIVE DISEASE; MALE; ORGAN TRANSPLANTATION; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; T LYMPHOCYTE; VIRUS LOAD;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL LOAD;

EID: 33847199387     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2006.10.006     Document Type: Article

References (47)

1. Rickinson A.B., and Kieff E. Epstein Barr virus. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. Third edition (2001) 2575-2627
2. Kieff E., and Rickinson A.B. Epstein Barr virus. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. Third edition (2001) 2511-2573
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transplant (1998) 147-158
4. Leblond V., Dhedin N., Mamzer Bruneel M.F., Choquet S., Hermine O., Porcher R., et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 19 (2001) 772-778
5. Papadopoulos E.B., Ladanyi M., Emanuel D., Mackinnon S., Boulad F., Carabasi M.H., et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330 (1994) 1185-1191
6. Heslop H.E., Brenner M.K., and Rooney C.M. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 331 (1994) 679-680
7. Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K., Sixbey J.W., Gan Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92 (1998) 1549-1555
8. Haque T., Wilkie G.M., Taylor C., Amlot P.L., Murad P., Iley A., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360 (2002) 436-442
9. Buell J.F., Gross T.G., and Woodle E.S. Malignancy after transplantation. Transplantation 80 (2005) S254-S264
10. Trofe J., Buell J.F., Beebe T.M., Hanaway M.J., First M.R., Alloway R.R., et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 5 (2005) 775-780
11. Gulley M.L., Swinnen L.J., Plaisance Jr. K.T., Schnell C., Grogan T.M., and Schneider B.G. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 76 (2003) 959-964
12. Ghobrial I.M., Habermann T.M., Macon W.R., Ristow K.M., Larson T.S., Walker R.C., et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?. Transplantation 79 (2005) 244-247
13. Rickinson A.B., and Moss D.J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15 (1997) 405-431
14. Murray R.J., Kurilla M.G., Brooks J.M., Thomas W.A., Rowe M., Kieff E., et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176 (1992) 157-168
15. Steven N.M., Leese A.M., Annels N.E., Lee S.P., and Rickinson A.B. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med 184 (1996) 1801-1813
16. Subklewe M., Chahroudi A., Bickham K., Larsson M., Kurilla M.G., Bhardwaj N., et al. Presentation of Epstein-Barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes. Eur J Immunol 29 (1999) 3995-4001
17. Leen A., Meij P., Redchenko I., Middeldorp J., Bloemena E., Rickinson A., et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 75 (2001) 8649-8659
18. Paludan C., and Munz C. CD4+T cell responses in the immune control against latent infection by Epstein-Barr virus. Curr Mol Med 3 (2003) 341-347
19. Munz C., Bickham K.L., Subklewe M., Tsang M.L., Chahroudi A., Kurilla M.G., et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 191 (2000) 1649-1660
20. Heller K.N., Upshaw J., Seyoum B., Zebroski H., and Munz C. Distinct memory CD4+T cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood (2006) (Sept 19)
21. Nikiforow S., Bottomly K., Miller G., and Munz C. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 77 (2003) 12088-12104
22. Mautner J., Pich D., Nimmerjahn F., Milosevic S., Adhikary D., Christoph H., et al. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+T helper cells. Eur J Immunol 34 (2004) 2500-2509
23. Long H.M., Haigh T.A., Gudgeon N.H., Leen A.M., Tsang C.W., Brooks J., et al. CD4+T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 79 (2005) 4896-4907
24. Piriou E., van Dort K., Nanlohy N.M., van Oers M.H., Miedema F., and van Baarle D. Loss of EBNA1-specific memory CD4+and CD8+T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 106 (2005) 3166-3174
25. Einsele H., Roosnek E., Rufer N., Sinzaer C., Riegler S., Loffler J., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99 (2002) 3916-3922
26. Ho W.Y., Yee C., and Greenberg P.D. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest 110 (2002) 1415-1417
27. Sun J.C., Williams M.A., and Bevan M.J. CD4+T cells are required for the maintenance, not programming, of memory CD8+T cells after acute infection. Nat Immunol 5 (2004) 927-933
28. Fu T., Voo K.S., and Wang R.F. Critical role of EBNA1-specific CD4+T cells in the control of mouse Burkitt lymphoma in vivo. J Clin Invest 114 (2004) 542-550
29. Kim A.Y., Lauer G.M., Ouchi K., Addo M.M., Lucas M., Schulze Zur Wiesch J., et al. The magnitude and breadth of hepatitis C virus-specific CD8+T cells depend on absolute CD4+T-cell count in individuals coinfected with HIV-1. Blood 105 (2005) 1170-1178
30. Adhikary D., Behrends U., Moosmann A., Witter K., Bornkamm G.W., and Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203 (2006) 995-1006
31. Baudouin V., Dehee A., Pedron-Grossetete B., Ansart-Pirenne H., Haddad E., Maisin A., et al. Relationship between CD8+T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study. Transplantation 77 (2004) 1706-1713
32. Meij P., van Esser J.W., Niesters H.G., van Baarle D., Miedema F., Blake N., et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101 (2003) 4290-4297
33. Smets F., Latinne D., Bazin H., Reding R., Otte J.B., Buts J.P., et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73 (2002) 1603-1610
34. Clave E., Agbalika F., Bajzik V., Peffault de Latour R., Trillard M., Rabian C., et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 77 (2004) 76-84
35. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
36. Oertel S., Trappe R.U., Zeidler K., Babel N., Reinke P., Hummel M., et al. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 85 (2006) 478-484
37. Macedo C., Donnenberg A., Popescu I., Reyes J., Abu-Elmaqd K., Shapiro R., et al. EBV-specific memory CD8+T cell phenotype and function in stable solid organ transplant patients. Transpl Immunol 14 (2005) 109-116
38. Kostense S., Vandenberghe K., Joling J., van Baarle D., Nanlohy N., Manting E., et al. Persistent numbers of tetramer+CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS. Blood 99 (2002) 2505-2511
39. Klenerman P., Cerundolo V., and Dunbar P.R. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2 (2002) 263-272
40. Rubio-Godoy V., Dutoit V., Rimoldi D., Lienard D., Leieune F., Speiser D., et al. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci U S A 98 (2001) 10302-10307
41. Goulder P.J., Tang Y., Brander C., De Rosa S.C., Douek D.C., Roederer M., et al. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med 192 (2000) 1819-1832
42. Betts M.R., Brenchley J.M., Price D.A., et al. Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation. J Immunol Methods 281 (2003) 65-78
43. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B.M., Eldridge R.L., et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407 (2000) 523-526
44. Altfeld M., and Rosenberg E.S. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol 12 (2000) 375-380
45. Piriou E.R., van Dort K., Nanlohy N.M., van Oers M.H., Miedema F., and van Baarle D. Novel method for detection of virus-specific CD41+T cells indicates a decreased EBV-specific CD4+T cell response in untreated HIV-infected subjects. Eur J Immunol 35 (2005) 796-805
46. Ducloux D., Carron P.L., Rebibou J.M., Rebibou J.M., Bresson-Vautrin C., Saint-Hillier Y., et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 65 (1998) 1270-1272
47. Ducloux D., Carron P.L., Motte G., Rebibou J.M., Bresson-Vautrin C., Tiberghien P., et al. Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. Transpl Int 15 (2002) 393-396